Biotechnology

Industry

Lilly Vaccines Push Expands With Three Acquisitions Worth Up to $3.8 Billion

Lilly vaccines strategy widened with three acquisitions worth up to $3.83 billion, giving the drugmaker new shingles, bacterial, and Epstein-Barr programs as obesity profits bankroll a prevention expansion in 2026.

Samuel Berrit OlamMay 27, 2026

Industry

Tubulis Acquisition Gives Gilead a New Oncology Platform

Tubulis acquisition gives Gilead a completed $5 billion oncology expansion, adding clinical-stage ADC assets, a Munich research base, and another pipeline bet as big drugmakers race to secure cancer growth.

Samuel Berrit OlamMay 26, 2026

Lilly Vaccines Push Expands With Three Acquisitions Worth Up to $3.8 Billion

Tubulis Acquisition Gives Gilead a New Oncology Platform

Trusted by growing brands

Official Partner Of